论文部分内容阅读
目的探讨分析前哨淋巴结(SLN)-T淋巴细胞免疫疗法治疗结直肠癌的可行性及安全性。方法选择2011年11月至2016年2月符合条件的55例结直肠癌患者,通过流式细胞仪检测分析SLN的亚群,并在体外培养扩增SLN-T淋巴细胞用于患者自体回输治疗,从而探讨SLN-T淋巴细胞治疗的临床可行性、安全性。本研究采用SPSS 17.0软件进行统计学分析,观察患者的基本临床特征及按照抗癌药物不良反应判定标准NCI-CTC 3.0版本对SLN细胞治疗过程中出现的不良反应进行安全性评价。结果 55例结直肠癌患者SLN中活化CD4~+T淋巴细胞数量明显高于外周血及肿瘤组织(P<0.05),且以免疫调节细胞为主,而非CD3~+CD8~+以及CD16~+CD56~+的杀伤细胞。SLN-T淋巴细胞过继性免疫治疗无明显不良反应,出现的不良反应经对症治疗后均可缓解。结论 SLN-T淋巴细胞过继性免疫疗法治疗结直肠癌患者,临床上是可行的,该治疗显示出良好的安全性和耐受性。
Objective To investigate the feasibility and safety of SLN-T lymphocyte immunotherapy in the treatment of colorectal cancer. Methods Fifty-five patients with colorectal cancer were eligible from November 2011 to February 2016. The subsets of SLN were analyzed by flow cytometry and the SLN-T lymphocytes were cultured and expanded in vitro for autologous transfusion So as to explore the clinical feasibility and safety of SLN-T lymphocyte therapy. In this study, SPSS 17.0 software was used for statistical analysis to observe the basic clinical features of the patients and to evaluate the safety of adverse reactions during the treatment of SLN cells according to the NCI-CTC 3.0 version of the standard of adverse drug reaction to anticancer drugs. Results The number of activated CD4 ~ + T lymphocytes in SLN of 55 patients with colorectal cancer was significantly higher than that in peripheral blood and tumor tissues (P <0.05). Immunoregulatory cells were the predominant in the colorectal cancer patients, but not CD3 ~ + CD8 ~ + and CD16 ~ + CD56 ~ + killer cells. Adoptive immunotherapy of SLN-T lymphocytes had no obvious adverse reactions, and the adverse reactions occurred could be relieved after symptomatic treatment. Conclusion Adoptive immunotherapy of SLN-T lymphocytes in patients with colorectal cancer is clinically feasible and the treatment shows good safety and tolerability.